Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,134 recalls, newest first

Class II · Moderate risk

CycloSPORINE Capsules

Failed Impurities/Degradations Specifications; out of specification results for Maximum Unknown Impurities and Total Impurities

Terminated Impurity / degradation Amerisource Health Services NDC 68084-921-25 D-0490-2017
Class III · Low risk

Levofloxacin Ophthalmic Solution

Failed Impurities/ Degradation Specifications: OOS for related compound (levofloxacin n-oxide) at the 18 month stability time point.

Terminated Impurity / degradation Actavis Inc NDC 50383-283-05 D-0514-2017
Class II · Moderate risk

Indocin (Indomethacin)

Failed Impurities/Degradation Specifications: Out of specification (OOS) for total impurity and out of trend for known impurity results encountered during stability testing.

Terminated Impurity / degradation G & W Laboratories, Inc. NDC 42211-0102-43 D-0501-2017
Class II · Moderate risk

GlipiZIDE Extended-release tablets

Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.

Terminated Dissolution failure Amerisource Health Services NDC 68084-295-21 D-0520-2017
Class II · Moderate risk

CycloSPORINE Capsules

Failed Impurities/Degradations Specifications; out of specification results for Maximum Unknown Impurities and Total Impurities.

Terminated Impurity / degradation Apotex Inc. NDC 60505-0134-0 D-0475-2017
Class III · Low risk

Q Care Continue Care Kit for the non-ventilated patient

Labeling: Incorrect or Missing Lot and/or Exp Date: The expiration date of the Q Care Continue Care kit is printed with an expiration date of November 13, 2017; rather than the correct date of August 28, 2017 (date of expiration of the Corinz Antiseptic Cleansing & Moisturizing Oral Rinse). Note, the correct expiration date of August 28, 2017, is printed on the Corinz Oral Rinse package.

Terminated Labeling / mix-up Sage Products Inc D-0489-2017
Class II · Moderate risk

Transderm Scop

Labeling: Incorrect Instructions:outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly.

Terminated Labeling / mix-up Sandoz Inc NDC 66758-208-58 D-0481-2017
Class III · Low risk

Norethindrone Acetate and Ethinyl Estradiol Tablets

Chemical Contamination: out of specification results for impurities were found to be the result of contamination of product from vapors associated with paint thinner used in repair of the manufacturing room.

Terminated Chemical / undeclared Mylan Pharmaceuticals Inc. NDC 0378-7280-85 D-0861-2017
Class III · Low risk

Tarina Fe 1/20

Chemical Contamination: out of specification results for impurities were found to be the result of contamination of product from vapors associated with paint thinner used in repair of the manufacturing room.

Terminated Chemical / undeclared Mylan Pharmaceuticals Inc. NDC 50102-128-01 D-0860-2017
Class II · Moderate risk

Glipizide extended-release tablets

Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.

Terminated Dissolution failure Actavis Inc NDC 0591-0900-30 D-0476-2017
Class III · Low risk

Buffered Lidocaine

Labeling; Label Mixup; outer packaging is incorrectly labeled as Buffered Lidocaine 1% instead of correctly as Buffered Lidocaine 0.9%

Terminated Labeling / mix-up Pharmedium Services, LLC D-0603-2017
Class II · Moderate risk

Mirtazapine Tablets

Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled

Terminated Particulate / foreign matter Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-088-20 D-0493-2017

Recalls by year